Empowered Funds LLC Sells 104,871 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Empowered Funds LLC reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 86.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,575 shares of the specialty pharmaceutical company's stock after selling 104,871 shares during the quarter. Empowered Funds LLC owned about 0.05% of Collegium Pharmaceutical worth $475,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in COLL. Victory Capital Management Inc. boosted its position in shares of Collegium Pharmaceutical by 43.6% in the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company's stock worth $27,461,000 after purchasing an additional 215,874 shares in the last quarter. Emerald Advisers LLC boosted its position in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company's stock worth $31,967,000 after purchasing an additional 177,129 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after acquiring an additional 175,892 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company's stock worth $25,591,000 after acquiring an additional 131,835 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Collegium Pharmaceutical by 17.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company's stock worth $29,586,000 after acquiring an additional 116,327 shares during the last quarter.

Wall Street Analyst Weigh In

COLL has been the subject of a number of recent analyst reports. Piper Sandler decreased their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Performance

COLL traded down $0.86 during mid-day trading on Friday, reaching $28.89. 74,294 shares of the company traded hands, compared to its average volume of 371,011. The stock has a market capitalization of $931.77 million, a P/E ratio of 12.45 and a beta of 0.82. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company's fifty day moving average price is $31.00 and its 200-day moving average price is $33.72. Collegium Pharmaceutical, Inc. has a 52-week low of $28.39 and a 52-week high of $42.29.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business's stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.